Codexis Inc是一家酶工程公司。该公司从事酶和其他蛋白质的发现、开发和销售。该公司运营两个分部:功能酶和新型生物治疗药物。该公司的CodeEvolver技术平台通过将起始酶转化为生物催化剂或治疗候选物来加速生物发现。该公司已将其CodeEvolver蛋白质工程技术平台和产品在制药市场商业化。其产品包括生物催化剂、化学中间体和Codex生物催化剂面板和试剂盒。该公司还将另外三种酶商业化,例如用于下一代测序的Codex HiFi DNA聚合酶、用于分子诊断应用的Codex HiTemp逆转录酶和用于RNA合成应用的Codex HiCap RNA聚合酶。该公司正在开发的主打项目CDX-6114,用于治疗高苯丙氨酸血症(HPA)。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Stephen George Dilly | Chairman | 2024 | 66 |
| Alison Moore | President, CEO & Director | 2025 | 59 |
| David V. Smith | Lead Independent Director | 2024 | 66 |
| Christos Richards | Director | 2025 | 69 |
| Cynthia L. Collins | Director | 2025 | 68 |
| James J. Lalonde | Member of Strategic Advisory Board | 2024 | 65 |
| Dennis P. Wolf | Independent Director | 2007 | 73 |
| Esther Martinborough | Independent Director | 2021 | 59 |
| Rahul Singhvi | Independent Director | 2022 | 61 |
| H. Stewart Parker | Independent Director | 2022 | 70 |
| Masad J. Damha | Member of Strategic Advisory Board | 2024 | - |
| John M. Maraganore | Member of Strategic Advisory Board | 2024 | 64 |
| Carole Beth Cobb | Member of Strategic Advisory Board | 2024 | 68 |
| Raymond De Vre | Director | 2024 | 58 |
| Arthur A. Levin | Member of Strategic Advisory Board | 2025 | 72 |